Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.
![](https://www.the-rheumatologist.org/wp-content/uploads/2020/12/OCMVWLVW-903959-2-ANY_CROPPED-1-150x150.jpg)